PMC:7647877 / 77052-77333
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T866 | 44-57 | Body_part | denotes | immune system | http://purl.org/sig/ont/fma/fma9825 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T174 | 44-57 | Body_part | denotes | immune system | http://purl.obolibrary.org/obo/UBERON_0002405 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1034 | 38-43 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
| T1035 | 44-57 | http://purl.obolibrary.org/obo/UBERON_0002405 | denotes | immune system |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T98419 | 198-203 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T477 | 0-281 | Sentence | denotes | Studying microbiota and therefore the human immune system and its dysregulation, or controlling the effects of postbiotics in the symbiotic status represents an important opportunity to develop new drugs, and combining probiotic supplements, with vaccines and immunotherapies [16]. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1683 | 38-43 | Species | denotes | human | Tax:9606 |